Total Payments
$21,218
2023 Payments
$3,102
Companies
15
Transactions
73
Medicare Patients
1,877
Medicare Billing
$261,264
Payment Breakdown by Category
Consulting$17,990 (84.8%)
Other$982.11 (4.6%)
Gifts$967.09 (4.6%)
Food & Beverage$693.40 (3.3%)
Research$461.85 (2.2%)
Education$124.06 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,990 | 13 | 84.8% |
| Long term medical supply or device loan | $982.11 | 11 | 4.6% |
| Gift | $967.09 | 7 | 4.6% |
| Food and Beverage | $693.40 | 38 | 3.3% |
| Unspecified | $461.85 | 1 | 2.2% |
| Education | $124.06 | 3 | 0.6% |
Payments by Type
General
$20,756
72 transactions
Research
$461.85
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $10,082 | 8 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $4,029 | 12 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $2,145 | 32 | $0 (2023) |
| Daiichi Sankyo Inc. | $1,943 | 1 | $0 (2022) |
| Puma Biotechnology, Inc. | $1,125 | 2 | $0 (2018) |
| Stemline Therapeutics Inc. | $1,080 | 1 | $0 (2023) |
| Eli Lilly and Company | $461.85 | 1 | $0 (2021) |
| Amgen Inc. | $99.95 | 1 | $0 (2019) |
| Allergan Inc. | $91.48 | 7 | $0 (2019) |
| Eisai Inc. | $45.10 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,102 | 14 | AstraZeneca Pharmaceuticals LP ($1,680) |
| 2022 | $6,210 | 9 | AstraZeneca Pharmaceuticals LP ($2,220) |
| 2021 | $3,550 | 12 | E.R. Squibb & Sons, L.L.C. ($2,556) |
| 2020 | $5,681 | 12 | E.R. Squibb & Sons, L.L.C. ($4,686) |
| 2019 | $1,385 | 12 | E.R. Squibb & Sons, L.L.C. ($1,136) |
| 2018 | $1,200 | 8 | Puma Biotechnology, Inc. ($1,125) |
| 2017 | $89.90 | 6 | AstraZeneca Pharmaceuticals LP ($46.88) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2023 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Prostate Cancer | ||||||
| 10/19/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.69 | General |
| 10/17/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $39.63 | General |
| 10/11/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Oncology | ||||||
| 08/11/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 06/15/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Oncology | ||||||
| 05/26/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $3.88 | General |
| Category: Oncology | ||||||
| 03/07/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Education | In-kind items and services | $12.19 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Eisai Inc. | Fycompa (Drug) | Food and Beverage | Cash or cash equivalent | $20.13 | General |
| Category: Neurology | ||||||
| 02/15/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 02/08/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| Category: Oncology | ||||||
| 02/04/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Oncology | ||||||
| 01/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 01/12/2023 | Eisai Inc. | Fycompa (Drug) | Food and Beverage | Cash or cash equivalent | $24.97 | General |
| Category: Neurology | ||||||
| 12/15/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 08/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,420.00 | General |
| 06/15/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 04/14/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $10.16 | General |
| Category: ONCOLOGY | ||||||
| 02/15/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $284.00 | General |
| Category: Oncology | ||||||
| 12/16/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,988.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $461.85 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 442 | 754 | $715,337 | $67,205 |
| 2022 | 9 | 504 | 773 | $697,347 | $68,675 |
| 2021 | 9 | 467 | 749 | $572,294 | $66,461 |
| 2020 | 9 | 464 | 766 | $249,634 | $58,923 |
Total Patients
1,877
Total Services
3,042
Medicare Billing
$261,264
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 260 | 400 | $335,352 | $29,827 | 8.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 70 | 231 | $271,208 | $26,229 | 9.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 49 | 49 | $70,282 | $7,583 | 10.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 39 | 40 | $23,785 | $1,765 | 7.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 22 | $10,208 | $1,501 | 14.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 11 | 12 | $4,502 | $299.94 | 6.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 243 | 356 | $296,684 | $26,898 | 9.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 69 | 200 | $234,810 | $24,553 | 10.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 49 | 49 | $70,597 | $7,338 | 10.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 51 | 59 | $34,711 | $2,904 | 8.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 21 | 21 | $23,025 | $2,209 | 9.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 33 | $15,066 | $2,022 | 13.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 18 | $11,721 | $1,577 | 13.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 20 | 25 | $6,209 | $829.25 | 13.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 11 | 12 | $4,524 | $343.94 | 7.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 237 | 422 | $310,592 | $34,075 | 11.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 50 | 107 | $105,395 | $13,516 | 12.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 31 | 31 | $43,183 | $4,861 | 11.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 62 | 85 | $43,265 | $4,805 | 11.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 34 | $23,392 | $3,086 | 13.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $17,368 | $2,288 | 13.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 27 | $12,879 | $1,705 | 13.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 13 | $11,817 | $1,553 | 13.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 16 | 17 | $4,403 | $572.39 | 13.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 220 | 356 | $108,224 | $22,268 | 20.6% |
About Dr. Anna Litvak, MD
Dr. Anna Litvak, MD is a Internal Medicine healthcare provider based in Livingston, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2012. The National Provider Identifier (NPI) number assigned to this provider is 1326319302.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anna Litvak, MD has received a total of $21,218 in payments from pharmaceutical and medical device companies, with $3,102 received in 2023. These payments were reported across 73 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($17,990).
As a Medicare-enrolled provider, Litvak has provided services to 1,877 Medicare beneficiaries, totaling 3,042 services with total Medicare billing of $261,264. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Livingston, NJ
- Active Since 01/23/2012
- Last Updated 05/02/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1326319302
Products in Payments
- ENHERTU (Drug) $1,943
- KISQALI (Drug) $1,918
- OPDIVO (Biological) $1,420
- Nerlynx (Drug) $1,125
- Orserdu (Drug) $1,080
- FASLODEX (Drug) $74.44
- LYNPARZA (Drug) $69.24
- NAMZARIC (Drug) $67.40
- PIQRAY (Drug) $45.81
- Fycompa (Drug) $45.10
- VRAYLAR (Drug) $24.08
- ELIGARD (Drug) $21.17
- Oncology (Device) $15.92
- TASIGNA (Drug) $14.67
- VERZENIO (Drug) $11.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Livingston
Dr. Fariborz Rezai, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Dr. Martin Bedigian, Md, MD
Internal Medicine — Payments: $894,400
Internal Medicine $894,400
Dr. Sridhar Nambi, Md, MD
Internal Medicine — Payments: $152,292
Internal Medicine $152,292
Dr. Noah Rosenberg, Md, MD
Internal Medicine — Payments: $148,109
Internal Medicine $148,109
Dr. Bruce Haik, M.d, M.D
Internal Medicine — Payments: $32,109
Internal Medicine $32,109
John Anton, M.d, M.D
Internal Medicine — Payments: $13,331
Internal Medicine $13,331